Butterfly Network Inc Revenue Growth Rates (BFLY), Current and Historic Growth - CSIMarket
CSIMarket
 


Butterfly Network Inc   (NYSE: BFLY)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

BFLY's Revenue Growth by Quarter and Year

Butterfly Network Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BFLY/growth
https://api.csimarket.com/api/v1/companies/BFLY/fundamentals
https://api.csimarket.com/api/v1/companies/BFLY/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
BFLY Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 32.60
2nd Quarter June 32.61
1st Quarter March 26.29
FY 91.50

BFLYs Annual Revenue
Butterfly Network Inc 's Revenue in the fiscal year 2025 $ 96.73 millions
Butterfly Network Inc 's Revenue in the fiscal year 2024 $ 81.83 millions
Butterfly Network Inc 's Revenue in the fiscal year 2023 $ 65.86 millions
Butterfly Network Inc 's Revenue in the fiscal year 2022 $ 73.39 millions
Butterfly Network Inc 's Revenue in the fiscal year 2021 $ 62.57 millions




BFLY Revenue third quarter 2026 Y/Y Growth Comment
Butterfly Network Inc achieved in the third quarter 2026, above Company average Revenue rise of 53.47% year on year, to $ 32.60 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 4 other companies have achieved higher Revenue growth. While Butterfly Network Inc ' s Revenue jump of 53.47% ranks overall at the positon no. 547 in the third quarter 2026.




BFLY Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 53.47 %
2nd Quarter June 42.46 %
1st Quarter March 29 %
FY   -

Financial Statements
Butterfly Network Inc 's third quarter 2026 Revenue $ 32.60 millions BFLY's Income Statement
Butterfly Network Inc 's third quarter 2025 Revenue $ 21.24 millions Quarterly BFLY's Income Statement


BFLY Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.04 %
2nd Quarter June 24.04 %
1st Quarter March -18.4 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #127
Overall #547

Revenue Y/Y Growth Statistics
High Average Low
44.26 % 14.03 % -19 %
(Dec 31 2021)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #5
Healthcare Sector #127
Overall #547
Revenue Y/Y Growth Statistics
High Average Low
44.26 % 14.03 % -19 %
(Dec 31 2021)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Butterfly Network Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
54.46 % 5.8 % -24.09 %
(Dec 31 2020)  


BFLY's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Butterfly Network Inc disclosed decrease in Revenue from the second quarter by -0.04% to $ 32.60 millions, from $ 32.61 millions achived in the previous reporting period.

But that's not important problem, as Butterfly Network Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Butterfly Network Inc 's Revenue growth quarter on quarter, overall rank is 442.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #95
Overall #442
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #95
Overall #442
Revenue Q/Q Growth Statistics
High Average Low
54.46 % 5.8 % -24.09 %
(Dec 31 2020)  


BFLY's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Butterfly Network Inc disclosed decrease in Revenue from the second quarter by -0.04% to $ 32.60 millions, from $ 32.61 millions achived in the previous reporting period.

But that's not important problem, as Butterfly Network Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Butterfly Network Inc 's Revenue growth quarter on quarter, overall rank is 442.


Butterfly Network Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 123.72
Y / Y Revenue Growth (TTM) 40.19 %
Year on Year Revenue Growth Overall Ranking # 698
Seqeuential Revenue Change (TTM) 10.11 %
Seq. Revenue Growth (TTM) Overall Ranking # 2338


Cumulative Revenue growth Comment
Butterfly Network Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 40.19% year on year, to $ 124 millions if the fiscal year would have ended in Sep 30 2026.
Butterfly Network Inc 's trailing twelve months Revenue growth was higher than company's average 12.12% and higher than 28.79% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 10.11 % from $112.36 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at12.12%.

In the Healthcare sector 145 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 518 to 698.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 146
Overall # 698

Revenue TTM Y/Y Growth Statistics
High Average Low
35.27 %
12.12 %
-10.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 337
S&P 500 # 2338
Cumulative Revenue growth Comment
Butterfly Network Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 40.19% year on year, to $ 124 millions if the fiscal year would have ended in Sep 30 2026.
Butterfly Network Inc 's trailing twelve months Revenue growth was higher than company's average 12.12% and higher than 28.79% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 10.11 % from $112.36 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at12.12%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 10.11 % increase from $112.36 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 145 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 518 to 698.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 146
Overall # 698

Revenue TTM Y/Y Growth Statistics
High Average Low
35.27 %
12.12 %
-10.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 337
S&P 500 # 2338




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BFLY's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions


About Butterfly Network Inc Revenue Growth Rates (BFLY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.